Curcumin For The Treatment Of Major Depression: A Randomised, Double-blind, Placebo Controlled Study
Notes for this study:
|Number of Subjects
||18-29, 30-44, 45-64
A total of 56 individuals with MDD were treated with 500 mg of BCM-95 curcumin (twice daily) or placebo for eight weeks. The primary measure was the IDS-SR30. Secondary outcomes included IDS-SR30 factor scores and the STAI. After eight weeks, The curcumin group experienced a 33.1% decrease in IDS-SR30 scores, a 19% decrease in STAI-S scores and a 14.8% decrease in STAI-T scores.
Funding issues for this study:
Funding for this study was provided by Arjuna Natural Extracts Limited.